Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 904 / https://doi.org/10.3332/ecancer.2019.904

Review

Women’s cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics

Over the last two decades, discoveries related to the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) have profoundly changed our understanding and management of hereditary breast and ovarian cancers. The concept of synthetic lethality, which arises when cells become vulnerable to a combination of deficiencies in DNA repair, has driven the expanding roles of poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitors in breast and ovarian cancers, and prevention strategies are taking into account the tissue specificity, natural history (fallopian tube origin of some high-grade serous ovarian cancers) and hormone sensitivity of BRCA-associated cancers. Current research has focussed on further elucidating the roles of BRCA proteins in DNA repair, investigating other key DNA repair processes and proteins and linking aberrant DNA repair with carcinogenesis. The ultimate goal is to translate this evolving knowledge into improving the clinical care and treatment of patients with pathogenic BRCA variants or other deficiencies in homologous recombination (HR). In this review, we will discuss 1) the role of BRCA proteins in DNA repair; 2) emerging concepts in the biology of HR deficiency and 3) implications for prevention and treatment.

Keywords: ovarian cancer, breast cancer, BRCA, BRCA1, BRCA2, homologous recombination, DNA repair, DNA damage response, highgrade serous ovarian cancer, triple negative breast cancer, PARP inhibitor, synthetic lethality, bilateral salpingo-oophorectomy, prophylacti

Loading Article Metrics ... Please wait

Related articles

Research: Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies

Abstract | Full Article | PDF Published: 10 Jul 2019 / https://doi.org/10.3332/ecancer.2019.937

Review: Challenges and shifting paradigms in clinical trials in oncology, the case for immunological and targeted therapies

Abstract | Full Article | PDF Published: 05 Jul 2019 / https://doi.org/10.3332/ecancer.2019.936

Research: Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

Abstract | Full Article | PDF Published: 27 Jun 2019 / https://doi.org/10.3332/ecancer.2019.935

Research: Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy

Abstract | Full Article | PDF Published: 06 Jun 2019 / https://doi.org/10.3332/ecancer.2019.934

Case Report: Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis

Abstract | Full Article | PDF Published: 03 Jun 2019 / https://doi.org/10.3332/ecancer.2019.933



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation